By
Drug Target Review2025-10-31T08:30:24
Scientists have discovered that two existing pain medications – bupivacaine and rimegepant – may not only relieve the severe pain caused by osteosarcoma but also slow the disease’s growth.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-07-10T09:00:00Z
2026-07-10T06:15:00Z
Contributor Professor Donald E Ingber, By Drug Target Review
2025-10-22T14:00:00
Sponsored by Wuxi Biologics
2025-05-08T10:38:52
Sponsored by Takara Bio USA
2024-01-10T08:56:17
Sponsored by Leica Microsystems
2023-12-11T10:49:07
Sponsored by Leica Microsystems
2026-07-10T06:15:00
Contributor Professor Donald E Ingber, By Drug Target Review
2023-07-04T10:05:58
Sponsored by Revvity
Site powered by Webvision Cloud